Cellular therapy: >=  days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
PART II: ANC >=  cells/mm^
ANC >/= cells/mcL (Cohort C)
ANC >=  X ^ /L with transfusions allowed if stem cells available
Cellular therapy: ? days after the completion of any type of cellular therapy (eg, modified T-cells, natural killer cells, dendritic cells, etc)
ANC  cells/?l
ANC <  cells/mm or <  cells/mm due to >% marrow involvement
ANC ? cells/mm
ANC ?  cells/?L or ?  cells/?L in subjects with documented bone marrow involvement, and independent of growth factor support  days before assessment.
ANC ?  cells/?L, or ?  cells/?L in subjects with documented bone marrow involvement, and independent of growth factor support  days before assessment.
Phase  subjects with known lymphoma: >= , cells/mm; >=, cells/mm for subjects with lymphoma in bone marrow
ANC >=  cells/mm^ (. x ^/L)
Participant has adequate hematological functions [absolute neutrophil count (ANC) ?  cells/microliter (mcL), hemoglobin ?  grams/deciliter (g/dL), and platelets ? , cells/mcL and ? , cells/mcL]
ANC ?  cells/L
Neutropenia ?  cells/l
Cellular Therapy: ? days after the completion of any type of cellular therapy (eg, modified T cells, natural killer cells, dendritic cells, etc)
ANC  cells/mL
ANC > cells/mm
ANC >  cells/mcl